Novo Holdings Set to Win EU Nod for $16.5B Catalent Deal, Source Says

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent, a person with direct knowledge of the matter said on Friday, clearing a key hurdle. Another source said Catalent is preparing senior management for the deal to go through. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profit from blockbuster weight-loss drug Wegovy has made it Europe’s most valuable company by market value.

Read the full article: Novo Holdings Set to Win EU Nod for $16.5B Catalent Deal, Source Says //

Source: https://www.reuters.com/markets/deals/eu-antitrust-regulators-set-okay-165-bln-novo-holdings-catalent-deal-source-says-2024-11-22/

Scroll to Top